Patient-reported outcomes
Larger improvements were observed in both PGIC and PI-MBS scores at Week 12 in the eptinezumab-treated group, with the mean PGIC scores being 2.6 for eptinezumab and 3.1 for placebo (Patient Global Impression of Change (When analyzing the change from baseline in Migraine-Specific Quality of Life Questionnaire subscores at Week 12 between treatments, role function for both restrictive (